Raphael Pharmaceutical Stock Performance
| RAPH Stock | 1.00 0.00 0.00% |
Raphael Pharmaceutical holds a performance score of 16 on a scale of zero to a hundred. The company holds a Beta of -1.71, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Raphael Pharmaceutical are expected to decrease by larger amounts. On the other hand, during market turmoil, Raphael Pharmaceutical is expected to outperform it. Use Raphael Pharmaceutical treynor ratio and rate of daily change , to analyze future returns on Raphael Pharmaceutical.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Raphael Pharmaceutical are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. Despite fairly fragile basic indicators, Raphael Pharmaceutical demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 95 K | |
| End Period Cash Flow | 153 K |
Raphael |
Raphael Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 26.00 in Raphael Pharmaceutical on December 24, 2024 and sell it today you would earn a total of 74.00 from holding Raphael Pharmaceutical or generate 284.62% return on investment over 90 days. Raphael Pharmaceutical is currently generating 2.7294% in daily expected returns and assumes 13.3274% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Raphael, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Raphael Pharmaceutical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Raphael Pharmaceutical's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Raphael Pharmaceutical, and traders can use it to determine the average amount a Raphael Pharmaceutical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2048
| Best Portfolio | Best Equity | |||
| Good Returns | RAPH | |||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 13.33 actual daily | 96 96% of assets are less volatile |
Expected Return
| 2.73 actual daily | 55 55% of assets have lower returns |
Risk-Adjusted Return
| 0.2 actual daily | 16 84% of assets perform better |
Based on monthly moving average Raphael Pharmaceutical is performing at about 16% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Raphael Pharmaceutical by adding it to a well-diversified portfolio.
Raphael Pharmaceutical Fundamentals Growth
Raphael OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Raphael Pharmaceutical, and Raphael Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Raphael OTC Stock performance.
| Return On Asset | -19.04 | |||
| Shares Outstanding | 15.62 M | |||
| EBITDA | (1.63 B) | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (1.42 M) | |||
| Total Asset | 422 K | |||
About Raphael Pharmaceutical Performance
By evaluating Raphael Pharmaceutical's fundamental ratios, stakeholders can gain valuable insights into Raphael Pharmaceutical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Raphael Pharmaceutical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Raphael Pharmaceutical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about Raphael Pharmaceutical performance evaluation
Checking the ongoing alerts about Raphael Pharmaceutical for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Raphael Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Raphael Pharmaceutical is way too risky over 90 days horizon | |
| Raphael Pharmaceutical has some characteristics of a very speculative penny stock | |
| Raphael Pharmaceutical appears to be risky and price may revert if volatility continues | |
| Raphael Pharmaceutical has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (1.62 B) with profit before overhead, payroll, taxes, and interest of 0. | |
| Raphael Pharmaceutical generates negative cash flow from operations |
- Analyzing Raphael Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Raphael Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining Raphael Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Raphael Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Raphael Pharmaceutical's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Raphael Pharmaceutical's otc stock. These opinions can provide insight into Raphael Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Raphael OTC Stock analysis
When running Raphael Pharmaceutical's price analysis, check to measure Raphael Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Raphael Pharmaceutical is operating at the current time. Most of Raphael Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Raphael Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Raphael Pharmaceutical's price. Additionally, you may evaluate how the addition of Raphael Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |